Zydus Lifesciences Ltd. has patented compounds reported to be useful for the treatment of osteoarthritis.

Prism Biolab Co. Ltd. has identified new 7-membered ring-fused compounds acting as Notch signaling inhibitors and reported to be potentially useful for the treatment of neuronal injury and neurodegenerative diseases.

Hyperway Pharmaceutical Co. Ltd. and Shenzhen Hyperway Pharmaceuticals Co. Ltd. have disclosed new GTPase KRAS (G12D mutant) inhibitors.

Bioversys AG has prepared rifabutin analogues reported to be useful for the treatment of bacterial infections.

Substituted fluorinated N-propyl-pyrrolidine and n-propyl-azetidine compounds acting as estrogen receptor (ER) antagonists and selective estrogen receptor degradation (SERD) inducers have been reported in a Sanofi SA patent.

Enanta Pharmaceuticals Inc. has patented heterocyclic compounds potentially useful for the treatment of metapneumovirus (MPV), influenza and respiratory syncytial virus (RSV) infections.

Merck KGaA scientists have identified new pyrido[3,2-d]pyrimidines acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors.

Chong Kun Dang Pharmaceutical Corp. has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, inflammation, neurodegeneration, autoimmune and neurological disorders.

Biolexis Therapeutics Inc. has divulged CDK9/cyclin T1 inhibitors reported to be useful for the treatment of cancer, inflammation and autoimmune disease.

Takeda Pharmaceutical Co. Ltd. has identified orexin OX2 receptor agonists reported to be useful for the treatment of narcolepsy.